G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$4.55 USD
+0.02 (0.44%)
Updated May 20, 2024 04:00 PM ET
After-Market: $4.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 161 - 180 ( 350 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q21: Key Word--EXECUTE On the COSELA Launch and New Clinical Trials
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Trial of Cosela in TNBC Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics Virtual Analyst and Investor Summit Focuses on Cosela Launch and Potential for SCLC Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
COSELA Kick Off: Spare the Marrow, Spear the Tumor
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Discusses COSELA Campaign: Spare the Marrow, Spear the Tumor
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Included in NCCN Oncology Guidelines. Raising Revenue.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Our Covered Companies at the 33rd ROTH Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q20 Results; Cosela Expected to be Commercially Available in Early March
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q20--COSELA Approved and Out of The Gate; More Clinical Trials Enrolling
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
With the Race Done, G1 Looks to Capitalize on COSELA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D